Happy New Year!

Our first #RheumJC of 2019 will be Thursday, January 31st at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Lancet article: Efficacy and safety of ustekinumab, an IL–12 and IL–23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

The next #RheumJC session will be Thursday, November 15th at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing four of our favorite abstracts from the ACR 2018 Annual Meeting, chosen by a combination of the #RheumJC team and your responses to our poll.

To cast your vote in our poll, click on this link (poll ends Wed Nov 14): https://twitter.com/RheumJC/status/1061722574533595137

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

The next #RheumJC session will be Thursday, September 27th at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

Based on this months (extremely close) poll, we’ll be doing the ARD BMJ article Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. This article is open access.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

The next #RheumJC session will be Thursday, August 30th at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

This month, as promised, we’re doing the JAMA article Association of Stress-Related Disorders With Subsequent Autoimmune Disease.

While this article is not open access, we’ll certainly be summarizing the article and discussing findings in typical journal club style. We hope you’ll join us and your online colleagues for this learning opportunity.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

The next #RheumJC session will be Thursday, July 26th at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We ran a fun experiment using Twitter polls to decide on this month’s #RheumJC, and in the end it came down to 1 vote (we’ll plan on doing the JAMA stress & autoimmunity article next month).

In the end, we’ll be doing the Annals of the Rheumatic Diseases article: Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

While this article is not open access, we’ll certainly be summarizing the article and discussing findings in typical journal club style. We hope you’ll join us and your online colleagues for this learning opportunity.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Our next #RheumJC session will be Thursday, June 28th at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Arthritis & Rheumatology article: 2015 American College of Rheumatology Workforce Study: The Role of Graduate Medical Education in Adult Rheumatology. (Direct link to pdf).

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Our next #RheumJC session will be Thursday, May 31st at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing the JAMA article: Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. (Link to full text from the VA website].

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Our next #RheumJC session will be Thursday, April 26th at:

UPDATED TIME: 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing the recent Journal of Autoimmunity article: The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Our next #RheumJC session will be Thursday, March 29th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the recent New England Journal of Medicine article: Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Our next #RheumJC session will be Thursday, February 22nd at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the recent Seminars in Arthritis & Rheumatism article: Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

1. Please remember to try to stay on topic whenever possible.
2. Be polite and courteous.
3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.